Syndax Pharmaceuticals has announced a new collaboration with Roche’s Genentech unit dedicated to combining small molecule cancer drug entinostat with the latter’s immunotherapy, Tecentriq.
In this work, Kamal, Knox et al develop a high-throughput system to identify small molecules that disrupt amyloid formation by pre-selecting compounds that suppress molecular interactions within ...
Neckers, Jeremy L. Davis, Choung D. Hoang, Jonathan M. Hernandez, David S. Schrump, R. Taylor Ripley. Induction of Thioredoxin-Interacting Protein by the Histone Deacetylase Inhibitor, Entinostat, ...